OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
Related Stories
ctDNA blood test pinpoints who needs chemo after colorectal liver surgery / 4 days
National study to use genetic testing to guide cancer survivor follow-up / 2 months
Ultrasensitive HPV blood test detects head and neck recurrence months earlier / 29 days
Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 6 wks
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 hrs
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 5 wks
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 5 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare, Gene Therapy, Supply Chain, Cybersecurity and look for the RSS link.
StackHealth Time Machine